{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268196","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.568638+00:00","generated_at":"2026-05-16T23:56:53.284639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Disc Medicine reports Q3 net loss of $62.3M; files NDA for bitopertin in EPP with priority review","bullets":["Submitted NDA for bitopertin in EPP seeking accelerated approval; FDA CNPV shortens review to 1-2 months; potential US launch late 2025/early 2026.","Cash and equivalents $615.9M as of Sep 30; Oct public offering added ~$211M net; cash runway extended into 2029.","R&D expenses $50.3M (up from $24.7M) driven by pipeline progression, including $10M milestone for DISC-3405.","Net loss widened to $62.3M from $26.6M in Q3 2024 due to higher operating costs for clinical programs and commercial prep.","Initial Phase 2 data for DISC-0974 in myelofibrosis anemia to be presented at ASH December 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268196","json":"https://secwatch.observer/filing/0001193125-25-268196.json","markdown":"https://secwatch.observer/filing/0001193125-25-268196.md","text":"https://secwatch.observer/filing/0001193125-25-268196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/0001193125-25-268196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312525268196/iron-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:56:53.284639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}